Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1B | P35368 | 5/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.41 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4027966 | 1.00 | ADRA1B (0.48) | ADRA1BKMT2AALDH1A1LMNAADRA1A | |
| SCHEMBL4024121 | 0.90 | NPC1 (0.43) | ADRA1BKMT2AALDH1A1ADRA1AUSP2 | |
| SCHEMBL4020789 | 0.90 | NPC1 (0.43) | ADRA1BKMT2AALDH1A1ADRA1AUSP2 | |
| SCHEMBL4020787 | 0.90 | NPC1 (0.43) | ADRA1BKMT2AALDH1A1ADRA1AUSP2 | |
| SCHEMBL4772529 | 0.84 | KCNH2 (0.43) | KMT2AALDH1A1ADRA1APOLBKCNH2 | |
| SCHEMBL4780151 | 0.84 | KCNH2 (0.43) | KMT2AALDH1A1ADRA1APOLBKCNH2 | |
| SCHEMBL4775780 | 0.83 | KCNH2 (0.40) | KMT2AALDH1A1LMNAKCNH2 | |
| SCHEMBL4773635 | 0.83 | KCNH2 (0.40) | KMT2AALDH1A1LMNAKCNH2 | |
| SCHEMBL4894830 | 0.82 | POLB (0.44) | KMT2AALDH1A1POLBKCNH2 | |
| SCHEMBL4795657 | 0.82 | POLB (0.44) | KMT2AALDH1A1POLBKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7572814-B2 | 3,5-dibenzoyl-4-phenyl-piperidine anti-cancer compounds | CYTOKINETICS, INCORPORATED (US) | 2009-08-11 | — | — | US | claimed |
| US-20070161674-A1 | Certain chemical entities, compositions, and methods | CYTOKINETICS, INC. | 2007-07-12 | — | — | US | claimed |
| US-7572814-B2 | 3,5-dibenzoyl-4-phenyl-piperidine anti-cancer compounds | CYTOKINETICS, INCORPORATED (US) | 2009-08-11 | — | — | US | disclosed |
| US-20070161674-A1 | Certain chemical entities, compositions, and methods | CYTOKINETICS, INC. | 2007-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070161674-A1 | Certain chemical entities, compositions, and methods | TP53, VHL, RB1 | ADRA1B 4417/4885KMT2A 2820/4885ALDH1A1 258/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.